

# Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease

## *Planning Phase II Trial*

VANCOUVER, BC – (November 19, 2018) – Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCD) (the “**Company**” or “Nash Pharma”) is pleased to announce that one of its lead compounds for chronic kidney disease (“CKD”) NP-135 showed positive results in a recently completed study investigating its therapeutic effects in a unilateral ureteral obstruction mouse model of kidney fibrosis. NP-135 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy. Repurposing drugs offer several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.

Data from this study demonstrated statistically significant improvements in multiple measurements over untreated controls relevant to chronic kidney disease including:

- A 43.1% (p=0.003) reduction in fibrosis as measured by Sirius red staining
- A reduction of blood urea nitrogen (BUN), a marker of kidney function (p=0.000047)
- Telmisartan, a positive control in the study and a current standard of care for CKD, reduced fibrosis by 42.2% (p=0.004)
- Telmisartan also reduced BUN but was not statistically significant
- NP-135 is a repurposed, orally delivered drug with no known anti-hypertensive effect.

“The CKD market segment has had very few new treatment options presenting in the last 25 years, despite the fact that 30 million people or 15% of US adults are estimated to have CKD,” said Christopher J. Moreau CEO of Nash Pharma. “We believe NP-135 could have a novel mechanism of action to treat fibrosis and are currently exploring its potential in other diseases affected by fibrosis as well”.

### **About Chronic Kidney Disease (“CKD”)**

CKD is a condition in which the kidneys are damaged or cannot filter blood as well as healthy kidneys, often as a result of fibrosis. Because of this, excess fluid and waste from the blood remain in the body and may cause other health problems.

### **Market Opportunity**

The global market for CKD drugs continues to proliferate at a significant pace, driven by the increasing number of CKD patients and the growing need of novel treatments to improve patients’ quality of life. According to Research and Markets, the global Chronic Kidney Disease (CKD) Drugs market was valued at US\$ 12.4B in 2016, and is expected to reach US\$ 17.4B by 2025, expanding at a CAGR of 3.9% from 2017 to 2025.

### **About Nash Pharmaceuticals Inc.**

Nash Pharma is a wholly owned subsidiary of Breathtec Biomedical Inc. Nash Pharma is a clinical stage pharmaceutical development company focused on drug repurposing in the

areas of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Drug repurposing is the process of discovering new therapeutic uses for existing drugs.

For more information, visit <https://nashpharmaceuticals.com/>.

## **CONTACT INFORMATION**

Christopher J. Moreau  
CEO  
Nash Pharmaceuticals Inc.  
604.398.4175 ext 701  
[info@breathtechbiomedical.com](mailto:info@breathtechbiomedical.com)  
[investors@breathtechbiomedical.com](mailto:investors@breathtechbiomedical.com)  
[www.breathtechbiomedical.com](http://www.breathtechbiomedical.com)

*CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*